Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1236272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Xinlu Zhan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Ovarian Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Nanchang University.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) is a fatal gynecological malignancy with limited therapeutic options. Previous research has demonstrated that Tripterygium glycosides (GTW) can enhance effectiveness of cisplatin (DDP) chemotherapy against EOC. However, the underlying mechanism of GTW alleviating EOC still remains unclear. In this article, an ID8 cell-derived xenograft mouse model was established to evaluate the anti-tumor efficacy of GTW combined with DDP. Consistent with previous findings, the results suggested that GTW combined with DDP can exhibit a stronger tumor suppressive effect than DDP alone. Additionally, GTW was found can further exert gastrointestinal protection against DDP by reducing pathological damage on colon tissue. Secondly, to verify whether gut microbiota play an instrumental role in GTW’s anticancer effect, we treated mice models with antibiotic to eliminate gut microbiota. And our experimental results indicated that all drug groups showed a weaker tumor suppressive effect and more severe gastrointestinal damage post antibiotic supplement. At genus level, the relative abundance of Lactobacillus was dramatically diminished by the antibiotic treatment, while combined treatment of GTW and DDP can significantly restore the level. Moreover, we performed Lactobacillus acidophilus transplantation and healthy mice fecal microbiota transplantation experiments to further investigate the link between the anticancer effect of GTW and gut microbiota. Our results suggested that both cisplatin-sensitizing and intestinal barrier-protecting effects of GTW can be recovered to a different extent. In conclusion, our results indicated that GTW is a promising chemosensitization and intestinal barrier repair drug for EOC, and the potential mechanism may corelate with the restoration of the compromised intestinal microbial balance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Obstetrics & Gynecology, Ji'an Central People's Hospital, Ji'an, China.
- Institute of Translational Medicine, Nanchang University, Nanchang, China.
Förderung
- National Natural Science Foundation of China
- Nanchang University
Zitieren
APA
Zhan, X., Zuo, Q., Huang, G., Qi, Z., Wang, Y., Zhu, S., Zhong, Y., Xiong, Y., Chen, T., & Tan, B. (2023). Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1236272
Vancouver
Zhan X, Zuo Q, Huang G, Qi Z, Wang Y, Zhu S, et al. Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1236272
BibTeX
@article{Zhan2023,
author = {Zhan, Xinlu and Zuo, Qi and Huang, Genhua and Qi, Zhanghua and Wang, Yufan and Zhu, Sihong and Zhong, Yanying and Xiong, Yifei and Chen, Tingtao and Tan, Buzhen},
title = {Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1236272}
}
EUVIMED